Key US Expert Group to Cast Ballots on Altering Infant Hepatitis B Vaccine Advisory
Following a hold-up and a particularly heated gathering, a government vaccine expert group was expected to vote on Friday regarding a potential change to the enduring advisory that every infant be inoculated against hepatitis B.
Fiery Exchange and a Deferred Vote
The first day of the conference on Thursday was characterized by heated debate over curbing eligibility to the hepatitis B vaccine for infants and a resolution to delay the ballot by a day to allow panelists additional time to scrutinize the phrasing. The panel, which advises the Centers for Disease Control and Prevention on vaccination protocols, had put off the vote twice in the past.
“Is there any specific evidence of injury of giving this immunization before 30 days? Or is this speculation?” asked one committee member.
In reply, another attendee stated, “There is inadequate data about the enduring danger.”
Existing Recommendations and Possible Consequences
The vaccine is presently advised for every newborn within 24 hours of delivery to stop transmission of hepatitis B, which can result in major damage to the liver. It has been provided to over a billion individuals for more than three decades.
The Atlanta conference offered no new evidence of injuries resulting from the vaccine. Specialists note any modification to the existing hepatitis B vaccine regimen could have profound and widespread implications for childhood health in the United States.
Panel Composition and Latest Shifts
The expert committee can only make recommendations to the head of the CDC. The group's roster has seen shifts in recent days, with the announcement that the group's former head would depart for an formal position and be substituted with a heart specialist who has been skeptical about other vaccines.
The panel includes multiple vaccination critics who support a desire to overhaul – and possibly, in some cases, abolish – long-established immunization guidelines.